The phase 1/2 ResQ133A-NMIBC trial (NCT06800963) is evaluating intravesical recombinant BCG in patients with BCG-naïve high-risk NMIBC across US sites, with safety as the primary end point and complete response and disease-free survival as secondary end points, building on European data showing 50% response rates and no dose-limiting toxicities in BCG-unresponsive disease.
Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC.
The 2025 AUA Census documents significant geographic maldistribution of the urologic workforce—with 62% of US counties lacking a urologist—alongside a median practitioner age of 54 and generational shifts in career expectations that together pose near-term workforce sustainability challenges.
The INTIBIA Pivotal Study—the first sham-controlled, double-blind RCT of an implantable tibial nerve stimulation device—demonstrated significantly greater clinically meaningful improvements in symptom bother, health-related quality of life, and patient global impression at 3 months compared with sham, with durable benefits through 12 months.
Chad A. Reichard, MD, highlights real-world data presented at AUA 2026 on re-induction with nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer.
ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality compared with a historical ADT control—while its use of propensity score matching with an external phase 3 control arm represents a novel trial design that may inform future studies in rapidly evolving treatment landscapes.
In this interview, Kari A.O. Tikkinen, MD, PhD, explains why effective nocturia management in geriatric patients requires systematic phenotyping across 4 primary subtypes—nocturnal polyuria, reduced bladder capacity, bladder outlet obstruction, and sleep-driven causes—rather than empiric pharmacologic treatment, with many cases requiring interdisciplinary referral rather than urologic intervention alone.
Health services research at UNC is informing community-based outreach efforts in prostate cancer—including engagement with HBCUs and patient groups across North Carolina—by centering patient and community perspectives to identify and address the barriers that prevent evidence-based care from reaching those who need it most.
Adam B. Weiner, MD, is joined by Mary Beth Westerman, MD, FACS, to discuss the landmark CISTO trial—a large pragmatic study examining patient-reported outcomes among individuals with high-risk non–muscle invasive bladder cancer who underwent either bladder-sparing therapy or radical cystectomy.
A real-world analysis found that PSADT was undocumented in most patients with high-risk biochemical recurrence of prostate cancer, potentially delaying treatment initiation and underestimating progression risk.
Krishnan discusses how prolapse stage, patient lifestyle, and nuanced mesh counseling inform individualized decision-making around robotic sacrocolpopexy vs vaginal reconstructive repair.
The 2026 AUA Annual Meeting will feature significant bladder cancer data, a plenary lecture on screening and overdetection, and programming that integrates advanced practice providers across sessions, against a backdrop of AUA-driven policy wins including removal of the vaginal estrogen black box warning and early steps toward a federal Office of Men's Health.
Isaac Y. Kim, MD, PhD, MBA, reflects on concerning trends in prostate cancer mortality, emphasizing how advances in diagnostics, treatment, and artificial intelligence may improve outcomes in the future.
C. Shawn West, MD, explores patient selection, symptom assessment, and clinical workflows guiding individualized treatment decisions in the MIST era.
Yeonsoo Sara Lee, MD, highlights the key networking and education opportunities she's most looking forward to at AUA 2026.
In the final installment of this 4-part series, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss the clinical value of enhanced cystoscopic imaging technologies and the operational barriers that may limit broader adoption in NMIBC care.
In part 3 of this 4-part series, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss practical strategies for communicating with pathologists when CIS is not clearly addressed in NMIBC pathology reports.
In part 2 of this 4-part series, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, examine how collaboration among urologists and pathologists, along with renewed attention to bladder mapping techniques, may improve CIS detection in NMIBC.
In this opening segment, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss how underreporting of CIS in pathology reports may limit access to guideline-supported therapies for patients with NMIBC.
Adam B. Weiner, MD, is joined by Nikita R. Bhatt, MBBS, MCh, MMed, FRCS, to discuss the WASHOUT study, a prospective international collaboration examining outcomes among patients admitted with emergency hematuria.
In this closing segment, Dr. Charles J. Ryan leads a discussion on how clinicians integrate multiple sources of evidence when making long term treatment decisions in metastatic castration sensitive prostate cancer (mCSPC).
In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians evaluate evidence from observational studies and propensity matched analyses in metastatic castration sensitive prostate cancer (mCSPC).
Charles R. Powell, MD, highlights 12-month data on the Neuspera System for urge urinary incontinence, reflecting on ideal candidates and the treatment's role alongside other SNM options.
PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics.
New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA.
Martin Gleave, MD, FRCSC, FACS, explains how the adaptive, biomarker-driven GUNS trial uses neoadjuvant therapy to link genomic subtypes with treatment response.
Advances in laser technology, morcellator design, and anesthetic approach have substantially improved HoLEP efficiency and patient recovery over the past decade, while surgeon-owned procedural checklists and pre-morcellation hemostasis remain the most critical safety practices for avoiding morcellator injury.
This video provides comprehensive review of current minimally invasive BPH therapies, focusing on safety, patient experience, and key distinctions between procedural categories.
Jennifer U. Miles-Thomas, MD, MBA, reflects on the key pillars to building successful surgeon/advanced practice providers partnerships.
In the FIT-001 trial, the combination of darlifarnib and cabozantinib demonstrated promising early antitumor activity in patients with ccRCC who had previously progressed on cabozantinib.
